Advances in the epidemiology, diagnosis and treatment of cryptosporidiosis

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 3, 2006, Pages 429-443

  Cacciò, Simmone M ^a   Pozio, Edoardo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cryptosporidium; Diagnosis; Epidemiology; Human; Immunocompromised individuals; Nitazoxanide; Treatment

Indexed keywords

AMPRENAVIR; ANTIPROTOZOAL AGENT; ATOVAQUONE; AZITHROMYCIN; CLARITHROMYCIN; COCCIDIOSTATIC AGENT; GLUTARALDEHYDE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN Y; INDINAVIR; INOSINATE DEHYDROGENASE INHIBITOR; MACROLIDE; NELFINAVIR; NITAZOXANIDE; PAROMOMYCIN; PROTEINASE INHIBITOR; RIFABUTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SPIRAMYCIN; THYMIDINE KINASE INHIBITOR; TIZOXANIDE; TIZOXANIDE GLUCURONIDE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIMICROBIAL THERAPY; CLINICAL TRIAL; COLOSTRUM; CROSS INFECTION; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DESIGN; DRUG METABOLISM; DRUG SCREENING; FLUID INTAKE; FOOD INTAKE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST PARASITE INTERACTION; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; MEDICAL RESEARCH; PARASITE TRANSMISSION; PASSIVE IMMUNIZATION; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT;

CRYPTOSPORIDIOSIS; HUMANS; IMMUNOCOMPROMISED HOST; OOCYSTS; RISK FACTORS; SEROLOGIC TESTS;

EID: 33745223028     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.3.429     Document Type: Review

References (86)

1. Thompson RC, Olson ME, Zhu G, Enomoto S, Abrahamsen MS, Hijjawi NS. Cryptosporidium and cryptosporidiosis. Adv. Parasitol. 59, 77-158 (2005).
2. Cacciò SM. Molecular epidemiology of human cryptosporidiosis. Parassitologia 47(2), 185-192 (2005).
3. Xiao L, Fayer R, Ryan U, Upton SJ. Cryptosporidium taxonomy: recent advances and implications for public health. Crit. Rev. Microbiol. 17, 72-97 (2004).
4. Fayer R, Morgan U, Upton SJ. Epidemiology of Cryptosporidium transmission, detection and identification. Int. J. Parasitol. 30(12-13), 1305-1322 (2000).
5. Dillingham RA, Lima AA, Guerrant RL. Cryptosporidiosis: epidemiology and impact. Microbes Infect. 4(10), 1059-1066 (2002).
6. Gomez Morales MA, Ausielio CM, Urbani F, Pozio E. Crude extract and recombinant protein of Cryptosporidium parvum oocysts induce proliferation of human peripheral blood mononuclear cells in vitro. J. Infect. Dis. 172, 211-216 (1995).
7. Current WL, Reese NC, Ernst JV, Bailey WS, Heyman MB, Weinstein WM. Human cryptosporidiosis in immunocompetent and immunodeficient persons. Studies of an outbreak and experimental transmission. N. Engl. J,. Med. 308, 1252-1257 (1983).
8. Hunter PR, Chalmers RM, Syed Q, Hughes LS, Woodhouse S, Swift L. Foot and mouth disease and cryptosporidiosis: possible interaction between two emerging infectious diseases. Emerg. Infect. Dis. 9, 109-112 (2003).
9. Smerdon WJ, Nichols T, Chalmers RM, Heine H, Reacher MH. Foot and mouth disease in livestock and reduced cryptosporidiosis in humans, England and Wales. Emerg. Infect. Dis. 9(1), 22-28 (2003).
10. Sopwith W, Osborn K, Chalmers R, Regan M. The changing epidemiology of cryptosporidiosis in North West England. Epidemiol. Infect. 133, 785-793 (2005).
11. Zhou L, Singh A, Jiang J, Xiao L. Molecular surveillance of Cryptosporidium spp. in raw wastewater in Milwaukee: implications for understanding outbreak occurrence and transmission dynamics. J. Clin. Microbiol. 41, 5254-5257 (2003).
12. Cacciò SM, Thompson RC, McLauchlin J, Smith HV. Unravelling Cryptosporidium and Giardia epidemiology. Trends Parasitol. 21(9), 430-437 (2005).
13. Goh S, Reacher M, Casemore DP et al. Sporadic cryptosporidiosis, North Cumbria, England, 1996-2000. Emerg. Infect. Dis. 10, 1007-1015 (2004).
14. Stantic-Pavlinic M, Xiao L, Glaberman S et al. Cryptosporidiosis associated with animal contacts. Wien Klin. Wochenschr. 15, 125-127 (2003).
15. Hunter P, Thomspon RC. The zoonotic transmission of Giardia and Cryptosporidium. Int. J. Parasitol. 35(11-12), 1181-1190 (2005).
16. Fayer R. Cryptosparidium: a water-borne zoonotic parasite. Vet. Parasitol. 126, 37-56 (2004).
17. MacKenzie WR, Hoxie NJ, Proctor ME et al. A massive outbreak in Milwaukee of Cryptosporidium infection transmi,tted through the public water supply. N. Engl. J. Med. 331, 161-167 (1994).
18. Corso PS, Kramer MH, Blair KA, Addiss DG, Davis JP, Haddix AC. Cost of illness in the 1993 waterborne Cryptosporidium outbreak, Milwaukee, Wisconsin. Emerg. Infect. Dis. 9, 426-431 (2003).
19. Slifko TR, Smith HV, Rose JB. Emerging parasite zoonoses associated with water and food. Int. J. Parasitol. 30, 1379-1393 (2000).
20. Millar BC, Finn M, Xiao L, Lowery CJ, Dooley JSG, Moore JE. Cryptosporidium in foodstuffs: an emerging aetiological route of human foodborne illness. Trends Food Sci. Technol. 3, 168-187 (2002).
21. Fayer R, Dubey JP, Lindsay DS. Zoonotic protozoa: from land to sea. Trends Parasitol. 20, 531-536 (2004).
22. Miller WA, Miller MA, Gardner IA et al. New genotypes and factors associated with Cryptosporidium detection in mussels (Mytilus spp.) along the California coast. Int. J. Parasitol. 35(10), 1103-1113 (2005).
23. Hunter PR, Nichols G. Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients. Clin. Microbiol. Rev. 15, 145-154 (2002).
24. Pozio E, Rezza G, Boschini A et al. Clinical cryptosporidiosis and human immunodeficiency virus (HIV)-induced immunosuppression: findings from a longitudinal study of HIV-positive and HIV-negative former injection drug users. J. Infect. Dis. 176, 969-975 (1997).
25. Hayward AR, Levy J, Facchetti F et al. Cholangiopathy and tumours of the pancreas, liver and biliary tree in boys with X-linked immunodeficiency with hyper-IgM syndrome. J. Immunol. 158, 977-983 (1997).
26. McLauchlin J, Amar CFL, Pedraza-Diaz S, Mieli-Verganti G, Hadzic N, Davies EG. Polymerase chain reaction-based diagnosis of infection with Cryptosporidium in children with primary immunodeficiencies. Pediatr. Infect. Dis. J. 22, 329-334 (2003).
27. Gomez Morales MA, Ausielio CM, Guarino A et al. Severe, protracted intestinal cryptosporidiosis associated with interferon-deficiency: pediatric case report. Clin. Infect. Dis. 22, 848-850 (1996).
28. Pozio, E, Rivasi F, Cacciò SM. Infection with Cryptosporidium hominis and reinfection with Cryptosporidium parvum in a transplanted ileum. APMIS 112, 309-313 (2004).
29. Thomas AG, Phillips AD, Walker-Smith JA. Cryptosporidiosis in England and Wales: prevalence and clinical and epidemiological features. Public Health Laboratory Service Study Group. Br. Med. J. 300, 774-777 (1990).
30. Sulaiman IM, Hira PR, Zhou L et al. Unique endemicity of cryptosporidiosis in children in Kuwait. J. Clin. Microbiol. 43(6), 2805-2809 (2005).
31. Berkman DS, Lescano AG, Gilman RH, Lopez SL, Black MM. Effects of stunting, diarrheal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study. Lancet 359, 564-571 (2002).
32. Tumwine JK, Kekitiinwa A, Nabukeera N et al. Cryptosporidium parvum in children with diarrhea in Mulago Hospital, Kampala, Uganda. Am. J. Trop. Med. Hyg. 68(6), 710-715 (2003).
33. Roy SL, DeLong SM, Stenzel SA et al. Risk factors for sporadic cryptosporidiosis among immunocompetent persons in the United States from 1999-2001. J. Clin. Microbiol. 42, 2944-2951 (2004).
34. Robertson B, Sinclair MI, Forbes AB et al. Case-control studies of sporadic cryptosporidiosis in Melbourne and Adelaide, Australia. Epidermiol. Infect. 128, 419-431 (2002).
35. Hunter PR, Hughes S, Woodhouse S et al. Sporadic cryptosporidiosis case-control study with genotyping. Emerg. Infect. Dis. 10, 1241-1249 (2004).
36. Hunter PR, Hughes S, Woodhouse S et al. Health sequelae of human cryptosporidiosis in immunocompetent patients. Clin. Infect. Dis. 39, 504-510 (2004).
37. Arrowood MJ. Diagnosis. In: Cryptosporidium and Cryptosporidiosis. Fayer R (Ed.), CRC Press, New York, London and Tokyo, 43-64 (1997).
38. Rondanelli EG, Scaglia M. Atlas of Human Protozoa. Masson, Milan, Paris and Bonn (1993).
39. Gomez Morales MA, Pozio E, Croppo GP. Serodiagnosis of human cryptosporidiosis in Italian HIV + patients using a soluble antigen by ELISA. J. Infect. 25, 229-236 (1992).
40. Priest JW, Li A, Khan M et al. Enzyme immunoassay detection of antigen-specific immunoglobulin G antibodies in longitudinal serum samples from human cryptosporidiosis patients. Clin. Diagn. Lab. Immunol. 8, 415-423 (2001).
41. Cacciò SM. Molecular techniques to detect and identify protozoan parasites in the environment. Acta Microbiol. Pol. 52, 23-34 (2003).
42. Armson A, Thompson RC, Reynoldson JA. A review of chemotherapeutic approaches to the treatment of cryptosporidiosis. Expert Rev. Anti Infect. Ther. 1(2), 297-305 (2003).
43. White CA Jr. Nitazoxanide: a new broad spectrum antiparasitic agent. Expert Rev. Anti Infect. Ther. 2(1), 43-49 (2004).
44. Gentile G, Venditti M, Micozzi A et al. Cryptosporidiosis in patients with hematologic malignancies. Rev. Infect. Dis. 13, 842-846 (1991).
45. Saez-Llorens X, Odio CM, Umana MA, Morales MV. Spiramycin vs. placebo for treatment of acute diarrhea caused by Cryptosporidium. Pediatr. Infect. Dis. J. 8, 136-140 (1989).
46. Moskovitz BL, Stanton TL, Kusmierek JJ. Spiramycin therapy for cryptosporidial diarrhoea in immunocompromised patients. J. Antimicrob. Chemother. 22(Suppl. B), 189-191 (1988).
47. Portnoy D, Whiteside ME, Buckley E III, MacLeod CL. Treatment of intestinal cryptosporidiosis with spiramycin. Ann. Intern. Med. 101, 202-204 (1984).
48. Kadappu KK, Nagaraja MV, Rao PV, Shastry BA. Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease. J. Postgrad. Med. 48, 179-181 (2002).
49. Chokephaibulkit K, Wanachiwanawin D, Tosasuk K, Pavitpok J, Vanprapar N, Chearskul S. Intestinal parasitic infections among human immunodeficiency virus-infected and -uninfected children hospitalized with diarrhea in Bangkok, Thailand. Southeast Asian J. Trop. Med. Public Health 32, 770-775 (2001).
50. Dionisio D, Orsi A, Sterrantino, G et al. Chronic cryptosporidiosis in patients with AIDS: stable remission and possible eradication after long-term, low dose azithromycin. J. Clin. Pathol. 51, 138-142 (1998).
51. Hicks P, Zwiener RJ, Squires J, Savell V. Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. J. Pediatr. 129, 297-300 (1996).
52. Jordan WC. Clarithromycin prophylaxis against. Cryptosporidium enteritis in patients with AIDS. J. Natl. Med. Assoc. 88, 425-427 (1996).
53. Holmberg SD, Moorman AC, Von Bargen JC et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. JAMA 279, 384-386 (1998).
54. Fichtenbaum CJ, Zackin R, Feinberg J, Benson C, Griffiths JK; AIDS Clinical Trials Group New Works Concept Sheet Team 064. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. AIDS 14, 2889-2893 (2000).
55. Hewitt RG, Yiannoutsos CT, Higgs ES et al. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin. Infect. Dis. 31, 1084-1092 (2000).
56. White AC Jr, Chappell CL, Hayat CS, Kimball KT, Flanigan TP, Goodgame RW. Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. J. Infect. Dis. 170, 419-424 (1994).
57. Bissuel F, Cotte L, Rabodonirina M, Rougier P, Piens MA, Trepo C. Paromomycin: an effective treatment for cryptosporidial diarrhea in patients with AIDS. Clin. Infect. Dis. 18, 447-449 (1994).
58. Fichtenbaum CJ, Ritchie DJ, Powderly WG. Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clin. Infect. Dis. 16, 298-300 (1993).
59. Rossignol JF, Hidalgo H, Feregrino M et al. A double-blind placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans. R. Soc. Trop. Med. Hyg. 92, 663-666 (1998).
60. Doumbo O, Rossignol JF, Pichard E et al. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg. 56, 637-639 (1997).
61. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J. Infect. Dis. 184, 103-106 (2001).
62. Amadi B, Mwiya M, Musuku J et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360, 1375-1380 (2002).
63. Nachbaur D, Kropshofer G, Feichtinger H, Allerberger F, Niederwieser D. Cryptosporidiosis after CD34-selected autologous peripheral blood stem cell transplantation (PBSCT). Treatment with paromomycin, azithromycin and recombinant human interleukin-2. Bone Marrow Transplant. 19, 1261-1263 (1997).
64. Smith NH, Cron S, Valdez LM, Chappell CL, White AC Jr. Combination drug therapy for cryptosporidiosis in AIDS. J. Infect Dis. 178, 900-903 (1998).
65. Riggs MW. Recent advances in cryptosporidiosis: the immune response. Microbes Infect. 4(10), 1067-1080 (2002).
66. Okhuysen PC, Chappell CL, Crabb J, Valdez LM, Douglass ET, DuPont HL. Prophylactic effect of bovine anti-Cryptosporidium hyperimmune colostrum immunoglobulin in healthy volunteers challenged with Cryptosporidium parvum. Clin. Infect. Dis. 26(6), 1324-1329 (1998).
67. Pozio E, Gomez Morales MA. The impact of HIV-protease inhibitors on opportunistic parasites. Trends Parasitol. 21(2), 58-63 (2005).
68. Babiker A, Darbyshire J, Pezzotti P et al. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int. J. Epidemiol. 31(5), 951-958 (2002).
69. Miao YM, Awad-El-Kariem FM, Franzen C et al. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 25, 124-129 (2000).
70. 3. Am. J. Gastroenterol. 95, 3142-3146 (2000).
71. Monkemuller KE, Call SA, Lazenby AJ, Wilcox CM. Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy. Am. J. Gastroenterol. 95, 457-462 (2000).
72. Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J. Infect. 42, 134-139 (2001).
73. Conti S, Masocco M, Pezzotti P et al. Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses. J. Acquir. Immune Defic. Syndr. 25, 451-458 (2000).
74. Schmidt W, Wahnschaffe U, Schafer M et al. Rapid increase of mucosal CD4 T cells followed by clearance of intestinal cryptosporidiosis in an AIDS patient receiving highly active antiretroviral therapy. Gastroenterology 120, 984-987 (2001).
75. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 351, 256-261 (1998).
76. Grube H, Ramratnam B, Ley C, Flanigan TP. Resolution of AIDS associated cryptosporidiosis after treatment with indinavir. Am. J. Gastroenterol. 92, 726 (1997).
77. Maggi P, Larocca AM, Quarto M, Serio G, Brandonisio O, Angarano G, Pastore G. Effect of antiretroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1. Eur. J. Clin. Microbiol. Infect. Dis. 19, 213-217 (2000).
78. Mele R, Gomez Morales MA, Tosini E, Pozio E. Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models. Int. J. Parasitol. 33, 757-764 (2003).
79. Hommer V, Eichholz J, Petry F. Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum. J. Antimicrob. Chemother. 52, 359-364 (2003).
80. Abrahamsen MS, Templeton TJ, Enomoto S et al. Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science 304, 441-445 (2004).
81. Xu P, Widmer G, Wang Y et al. The genome of Cryptosporidium hominis. Nature 431, 1107-1112 (2004).
82. Wiesner J, Seeber F. The plastid-derived organelle of protozoan human parasites as a target of established and emerging drugs. Expert Opin. Ther. Targets 9, 23-44 (2005).
83. Camps M, Arrizabalaga G, Boothroyd J. An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii. Mol. Microbiol. 43, 1309-1318 (2002)
84. Baggish AL, Hill DR. Antiparasitic agent atovaquone. Antimicrob. Agents Chemother. 46, 1163-1173 (2002).
85. Striepen B, Pruijssers AJ, Huang J et al. Gene transfer in the evolution of parasite nucleotide biosynthesis. Proc. Natl. Acad. Sci. USA 101, 3154-3159 (2001).
86. Umejiego NN, Li C, Riera T, Hedstrom L, Striepen B. Cryptosporidium parvum IMP dehydrogenase: identification of functional, structural, and dynamic properties that can be exploited for drug design. J. Biol. Chem. 279, 40320-40327 (2004).